Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pulmonary Embolism | 101 | 2024 | 2596 | 14.480 |
Why?
|
Venous Thromboembolism | 63 | 2024 | 1883 | 10.030 |
Why?
|
Anticoagulants | 67 | 2025 | 4857 | 6.310 |
Why?
|
Thrombosis | 23 | 2025 | 2955 | 5.100 |
Why?
|
Venous Thrombosis | 27 | 2024 | 1321 | 4.910 |
Why?
|
Vena Cava Filters | 14 | 2024 | 270 | 4.700 |
Why?
|
Fibrinolytic Agents | 20 | 2024 | 2077 | 4.050 |
Why?
|
Thromboembolism | 8 | 2024 | 1001 | 2.060 |
Why?
|
Hemorrhage | 35 | 2025 | 3466 | 2.020 |
Why?
|
Enoxaparin | 4 | 2023 | 391 | 2.000 |
Why?
|
Registries | 45 | 2024 | 8347 | 1.940 |
Why?
|
Heparin | 8 | 2024 | 1635 | 1.910 |
Why?
|
Hirudins | 5 | 2024 | 179 | 1.880 |
Why?
|
Acute Disease | 42 | 2024 | 7237 | 1.530 |
Why?
|
Randomized Controlled Trials as Topic | 25 | 2025 | 10380 | 1.360 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2024 | 3249 | 1.240 |
Why?
|
Platelet Aggregation Inhibitors | 7 | 2024 | 2768 | 1.160 |
Why?
|
Atrial Fibrillation | 8 | 2024 | 5185 | 1.100 |
Why?
|
Cardiology | 7 | 2024 | 1696 | 1.100 |
Why?
|
Hospitalization | 18 | 2024 | 10811 | 1.060 |
Why?
|
Humans | 225 | 2025 | 766117 | 1.050 |
Why?
|
Endocarditis | 3 | 2015 | 349 | 1.050 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 3 | 2018 | 156 | 1.040 |
Why?
|
Gastrointestinal Diseases | 2 | 2024 | 1204 | 1.000 |
Why?
|
Ventricular Dysfunction, Right | 6 | 2024 | 645 | 1.000 |
Why?
|
Vena Cava, Inferior | 5 | 2024 | 463 | 0.930 |
Why?
|
Thrombolytic Therapy | 9 | 2024 | 2051 | 0.920 |
Why?
|
Cardiovascular Diseases | 16 | 2024 | 15647 | 0.910 |
Why?
|
Postthrombotic Syndrome | 2 | 2022 | 29 | 0.900 |
Why?
|
Vitamin K | 2 | 2024 | 312 | 0.870 |
Why?
|
Embolectomy | 1 | 2024 | 130 | 0.870 |
Why?
|
Antithrombins | 2 | 2024 | 295 | 0.870 |
Why?
|
Risk Assessment | 36 | 2024 | 24276 | 0.810 |
Why?
|
Heart Diseases | 4 | 2020 | 2818 | 0.800 |
Why?
|
Journal Impact Factor | 4 | 2020 | 157 | 0.800 |
Why?
|
Helicobacter Infections | 2 | 2024 | 390 | 0.770 |
Why?
|
Fibric Acids | 1 | 2021 | 27 | 0.770 |
Why?
|
Administration, Oral | 7 | 2025 | 4016 | 0.760 |
Why?
|
Peptide Fragments | 5 | 2024 | 5126 | 0.760 |
Why?
|
International Classification of Diseases | 2 | 2024 | 934 | 0.760 |
Why?
|
Vaccination | 4 | 2023 | 3431 | 0.750 |
Why?
|
Recurrence | 23 | 2024 | 8494 | 0.740 |
Why?
|
Helicobacter pylori | 2 | 2024 | 380 | 0.730 |
Why?
|
Saphenous Vein | 3 | 2013 | 519 | 0.730 |
Why?
|
Antiphospholipid Syndrome | 1 | 2022 | 165 | 0.720 |
Why?
|
P-Selectin | 1 | 2023 | 598 | 0.720 |
Why?
|
Niacin | 1 | 2021 | 116 | 0.710 |
Why?
|
Glycosaminoglycans | 2 | 2020 | 606 | 0.710 |
Why?
|
Iran | 7 | 2022 | 760 | 0.710 |
Why?
|
Coronavirus Infections | 5 | 2020 | 3111 | 0.700 |
Why?
|
Periodicals as Topic | 5 | 2024 | 1463 | 0.700 |
Why?
|
Pneumonia, Viral | 5 | 2020 | 3233 | 0.700 |
Why?
|
Risk Factors | 49 | 2024 | 74857 | 0.690 |
Why?
|
Sinus Thrombosis, Intracranial | 1 | 2021 | 110 | 0.680 |
Why?
|
Muscular Diseases | 1 | 2024 | 551 | 0.670 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 3 | 2024 | 3247 | 0.670 |
Why?
|
Troponin I | 1 | 2024 | 656 | 0.650 |
Why?
|
Warfarin | 2 | 2025 | 1494 | 0.630 |
Why?
|
Zinc | 2 | 2020 | 675 | 0.630 |
Why?
|
Coronary Artery Bypass | 6 | 2021 | 2188 | 0.620 |
Why?
|
Pandemics | 11 | 2023 | 8725 | 0.620 |
Why?
|
Patient Discharge | 5 | 2024 | 3465 | 0.620 |
Why?
|
Oxygen Inhalation Therapy | 2 | 2022 | 419 | 0.610 |
Why?
|
Heart Failure | 10 | 2020 | 11837 | 0.610 |
Why?
|
Endpoint Determination | 2 | 2020 | 591 | 0.590 |
Why?
|
Aged | 66 | 2025 | 171219 | 0.590 |
Why?
|
Triage | 2 | 2024 | 994 | 0.590 |
Why?
|
Thrombophilia | 1 | 2020 | 308 | 0.570 |
Why?
|
Cardiac Tamponade | 1 | 2019 | 175 | 0.570 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2018 | 102 | 0.560 |
Why?
|
Outpatients | 2 | 2024 | 1596 | 0.540 |
Why?
|
Pericardial Effusion | 1 | 2019 | 245 | 0.540 |
Why?
|
Treatment Outcome | 35 | 2025 | 65219 | 0.540 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2024 | 1127 | 0.540 |
Why?
|
Extracorporeal Membrane Oxygenation | 3 | 2024 | 1480 | 0.520 |
Why?
|
Female | 88 | 2025 | 396233 | 0.520 |
Why?
|
Ankle | 1 | 2019 | 353 | 0.520 |
Why?
|
Heart Atria | 2 | 2020 | 1363 | 0.510 |
Why?
|
Male | 80 | 2025 | 363935 | 0.500 |
Why?
|
Foot | 1 | 2019 | 576 | 0.490 |
Why?
|
Femoral Vein | 1 | 2016 | 156 | 0.490 |
Why?
|
Fee-for-Service Plans | 2 | 2018 | 713 | 0.460 |
Why?
|
Neoplasms | 9 | 2024 | 22344 | 0.460 |
Why?
|
Guideline Adherence | 7 | 2018 | 2235 | 0.440 |
Why?
|
Predictive Value of Tests | 7 | 2024 | 15403 | 0.430 |
Why?
|
Middle Aged | 54 | 2025 | 223083 | 0.420 |
Why?
|
Lower Extremity | 4 | 2020 | 1218 | 0.420 |
Why?
|
Recombinant Proteins | 5 | 2024 | 6493 | 0.400 |
Why?
|
Pyridones | 3 | 2023 | 817 | 0.400 |
Why?
|
Furosemide | 1 | 2013 | 174 | 0.400 |
Why?
|
Stroke | 5 | 2023 | 9748 | 0.390 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2021 | 1399 | 0.390 |
Why?
|
Occupations | 1 | 2014 | 516 | 0.390 |
Why?
|
Databases, Factual | 11 | 2024 | 8062 | 0.390 |
Why?
|
Intensive Care Units | 6 | 2023 | 3798 | 0.380 |
Why?
|
Prognosis | 23 | 2024 | 29912 | 0.380 |
Why?
|
Medicare | 7 | 2023 | 6820 | 0.380 |
Why?
|
Myocardial Infarction | 4 | 2023 | 11509 | 0.380 |
Why?
|
Education | 1 | 2014 | 531 | 0.370 |
Why?
|
Plaque, Atherosclerotic | 2 | 2013 | 1529 | 0.370 |
Why?
|
Aged, 80 and over | 32 | 2024 | 59515 | 0.370 |
Why?
|
Streptococcal Infections | 1 | 2015 | 616 | 0.360 |
Why?
|
Fluid Therapy | 1 | 2015 | 587 | 0.360 |
Why?
|
Population Surveillance | 1 | 2021 | 2596 | 0.360 |
Why?
|
Algorithms | 6 | 2024 | 14066 | 0.350 |
Why?
|
Heart Valve Diseases | 2 | 2015 | 1029 | 0.350 |
Why?
|
Congresses as Topic | 1 | 2015 | 811 | 0.350 |
Why?
|
Hospital Mortality | 7 | 2021 | 5340 | 0.340 |
Why?
|
Data Interpretation, Statistical | 1 | 2019 | 2689 | 0.330 |
Why?
|
Antiviral Agents | 5 | 2023 | 3068 | 0.330 |
Why?
|
Prospective Studies | 26 | 2025 | 54812 | 0.330 |
Why?
|
Thrombocytopenia | 3 | 2022 | 1172 | 0.320 |
Why?
|
United States | 25 | 2024 | 72920 | 0.320 |
Why?
|
Liver Cirrhosis | 1 | 2019 | 1961 | 0.320 |
Why?
|
Patient Readmission | 7 | 2023 | 3283 | 0.310 |
Why?
|
National Health Programs | 1 | 2012 | 444 | 0.310 |
Why?
|
Disease Progression | 3 | 2024 | 13616 | 0.310 |
Why?
|
Acute Coronary Syndrome | 4 | 2022 | 2185 | 0.300 |
Why?
|
Research Design | 3 | 2020 | 6206 | 0.300 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2020 | 345 | 0.290 |
Why?
|
Echocardiography | 3 | 2024 | 5041 | 0.290 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2015 | 1563 | 0.290 |
Why?
|
Hemostasis | 2 | 2020 | 467 | 0.290 |
Why?
|
Preventive Health Services | 1 | 2012 | 571 | 0.280 |
Why?
|
Spain | 6 | 2021 | 483 | 0.280 |
Why?
|
Atherosclerosis | 2 | 2013 | 3418 | 0.270 |
Why?
|
Staphylococcal Infections | 1 | 2015 | 1393 | 0.270 |
Why?
|
C-Reactive Protein | 2 | 2024 | 3853 | 0.260 |
Why?
|
Blood Coagulation | 1 | 2012 | 1169 | 0.260 |
Why?
|
Cause of Death | 7 | 2024 | 3715 | 0.260 |
Why?
|
Income | 1 | 2014 | 1874 | 0.250 |
Why?
|
Residence Characteristics | 2 | 2014 | 2116 | 0.240 |
Why?
|
Patient Care Management | 2 | 2018 | 301 | 0.240 |
Why?
|
Length of Stay | 5 | 2022 | 6490 | 0.240 |
Why?
|
Internal Medicine | 1 | 2011 | 1064 | 0.230 |
Why?
|
Purinergic P2Y Receptor Antagonists | 3 | 2022 | 285 | 0.230 |
Why?
|
Clinical Trials as Topic | 2 | 2017 | 8038 | 0.230 |
Why?
|
Inflammation | 3 | 2020 | 10860 | 0.220 |
Why?
|
Ultrasonography | 2 | 2020 | 5988 | 0.220 |
Why?
|
Pulmonary Artery | 2 | 2024 | 1938 | 0.220 |
Why?
|
Cohort Studies | 9 | 2024 | 41684 | 0.220 |
Why?
|
Reperfusion | 2 | 2023 | 268 | 0.210 |
Why?
|
Vascular Diseases | 1 | 2011 | 1161 | 0.210 |
Why?
|
Sulfonamides | 1 | 2013 | 1980 | 0.210 |
Why?
|
Freedom | 1 | 2023 | 69 | 0.210 |
Why?
|
Practice Guidelines as Topic | 10 | 2024 | 7424 | 0.210 |
Why?
|
Lipoprotein(a) | 1 | 2008 | 488 | 0.210 |
Why?
|
Postoperative Complications | 3 | 2020 | 15808 | 0.210 |
Why?
|
Catheters | 2 | 2023 | 427 | 0.210 |
Why?
|
Survival Rate | 9 | 2024 | 12827 | 0.210 |
Why?
|
Health Promotion | 2 | 2012 | 2209 | 0.210 |
Why?
|
Time Factors | 15 | 2024 | 40108 | 0.210 |
Why?
|
Europe | 3 | 2019 | 3430 | 0.210 |
Why?
|
Ventricular Function, Right | 2 | 2024 | 629 | 0.210 |
Why?
|
United States Food and Drug Administration | 2 | 2024 | 1673 | 0.200 |
Why?
|
Oral Surgical Procedures | 1 | 2024 | 172 | 0.200 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2006 | 0.200 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4853 | 0.200 |
Why?
|
Heart Ventricles | 3 | 2025 | 3833 | 0.200 |
Why?
|
Risk | 4 | 2019 | 9599 | 0.200 |
Why?
|
Sex Characteristics | 2 | 2023 | 2646 | 0.190 |
Why?
|
Incidence | 10 | 2024 | 21513 | 0.190 |
Why?
|
Lipid Regulating Agents | 1 | 2021 | 21 | 0.190 |
Why?
|
Disease Management | 2 | 2013 | 2531 | 0.190 |
Why?
|
Bibliometrics | 2 | 2016 | 356 | 0.190 |
Why?
|
Dental Care | 1 | 2024 | 286 | 0.190 |
Why?
|
Patient Education as Topic | 1 | 2011 | 2332 | 0.190 |
Why?
|
Adult | 24 | 2025 | 223139 | 0.190 |
Why?
|
Angiography | 3 | 2021 | 1589 | 0.180 |
Why?
|
Pyrazoles | 2 | 2021 | 2031 | 0.180 |
Why?
|
Coronary Artery Disease | 3 | 2021 | 6544 | 0.180 |
Why?
|
Anti-Inflammatory Agents | 2 | 2020 | 1805 | 0.180 |
Why?
|
Esters | 1 | 2021 | 213 | 0.180 |
Why?
|
Drug Administration Routes | 1 | 2020 | 152 | 0.170 |
Why?
|
Sulfhydryl Compounds | 1 | 2021 | 296 | 0.170 |
Why?
|
Troponin | 2 | 2023 | 532 | 0.170 |
Why?
|
Heart Rate | 2 | 2022 | 4204 | 0.170 |
Why?
|
Internationality | 3 | 2024 | 1007 | 0.170 |
Why?
|
Embolism | 1 | 2023 | 401 | 0.170 |
Why?
|
Hallux Valgus | 1 | 2020 | 67 | 0.160 |
Why?
|
Public Health | 1 | 2012 | 2681 | 0.160 |
Why?
|
Amides | 1 | 2021 | 451 | 0.160 |
Why?
|
Withholding Treatment | 2 | 2024 | 619 | 0.150 |
Why?
|
Tissue Plasminogen Activator | 2 | 2021 | 1164 | 0.150 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2022 | 1898 | 0.150 |
Why?
|
Syndrome | 2 | 2021 | 3270 | 0.150 |
Why?
|
Uncertainty | 1 | 2023 | 763 | 0.150 |
Why?
|
Comorbidity | 5 | 2024 | 10579 | 0.150 |
Why?
|
Sex Factors | 4 | 2023 | 10614 | 0.150 |
Why?
|
Smoke | 1 | 2019 | 243 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2021 | 10737 | 0.140 |
Why?
|
Double-Blind Method | 2 | 2023 | 12426 | 0.140 |
Why?
|
Research Report | 1 | 2020 | 367 | 0.140 |
Why?
|
Graft Occlusion, Vascular | 2 | 2012 | 539 | 0.140 |
Why?
|
Healthcare Disparities | 4 | 2020 | 3407 | 0.140 |
Why?
|
Reproducibility of Results | 3 | 2024 | 20137 | 0.140 |
Why?
|
Protein Structure, Secondary | 1 | 2020 | 1211 | 0.140 |
Why?
|
Publishing | 2 | 2018 | 836 | 0.130 |
Why?
|
Retrospective Studies | 17 | 2023 | 81565 | 0.130 |
Why?
|
Pericarditis | 1 | 2018 | 135 | 0.130 |
Why?
|
Death, Sudden, Cardiac | 1 | 2024 | 1568 | 0.130 |
Why?
|
Follow-Up Studies | 9 | 2020 | 39243 | 0.130 |
Why?
|
Severity of Illness Index | 6 | 2024 | 15882 | 0.130 |
Why?
|
Tachycardia | 1 | 2018 | 598 | 0.130 |
Why?
|
Ischemia | 3 | 2021 | 1904 | 0.130 |
Why?
|
History, 20th Century | 1 | 2024 | 2762 | 0.130 |
Why?
|
Drug Interactions | 1 | 2020 | 1419 | 0.130 |
Why?
|
Confusion | 1 | 2018 | 278 | 0.120 |
Why?
|
Inpatients | 2 | 2022 | 2566 | 0.120 |
Why?
|
Organ Specificity | 1 | 2020 | 1966 | 0.120 |
Why?
|
Multicenter Studies as Topic | 1 | 2020 | 1729 | 0.120 |
Why?
|
Age Factors | 5 | 2023 | 18386 | 0.120 |
Why?
|
Health Care Costs | 3 | 2013 | 3243 | 0.120 |
Why?
|
Veins | 1 | 2019 | 769 | 0.120 |
Why?
|
Puerperal Disorders | 1 | 2018 | 304 | 0.120 |
Why?
|
Emergencies | 1 | 2021 | 1224 | 0.120 |
Why?
|
Isotonic Solutions | 1 | 2015 | 119 | 0.120 |
Why?
|
Sex Distribution | 2 | 2024 | 2270 | 0.120 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2024 | 1249 | 0.120 |
Why?
|
Saline Solution, Hypertonic | 1 | 2015 | 116 | 0.110 |
Why?
|
Surgical Wound Dehiscence | 1 | 2015 | 215 | 0.110 |
Why?
|
Telecommunications | 1 | 2014 | 79 | 0.110 |
Why?
|
Pilot Projects | 2 | 2025 | 8724 | 0.110 |
Why?
|
Age Distribution | 2 | 2024 | 2865 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1084 | 0.110 |
Why?
|
Pregnancy | 5 | 2024 | 30233 | 0.110 |
Why?
|
Aorta | 1 | 2021 | 2040 | 0.110 |
Why?
|
Malnutrition | 1 | 2020 | 629 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6506 | 0.110 |
Why?
|
Infusions, Intravenous | 2 | 2015 | 2227 | 0.110 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2018 | 518 | 0.110 |
Why?
|
Blood Pressure | 3 | 2020 | 8532 | 0.110 |
Why?
|
Antihypertensive Agents | 2 | 2013 | 2028 | 0.100 |
Why?
|
Vaccines | 1 | 2021 | 840 | 0.100 |
Why?
|
Renal Replacement Therapy | 1 | 2015 | 282 | 0.100 |
Why?
|
Medical Informatics | 1 | 2019 | 743 | 0.100 |
Why?
|
Hypotension | 1 | 2018 | 885 | 0.100 |
Why?
|
Stockings, Compression | 1 | 2012 | 36 | 0.100 |
Why?
|
Cardiology Service, Hospital | 1 | 2014 | 242 | 0.100 |
Why?
|
Evidence-Based Medicine | 3 | 2012 | 3690 | 0.100 |
Why?
|
Intracranial Hemorrhages | 1 | 2017 | 810 | 0.100 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2024 | 2184 | 0.100 |
Why?
|
Odds Ratio | 2 | 2021 | 9657 | 0.100 |
Why?
|
Canada | 2 | 2019 | 2120 | 0.090 |
Why?
|
Neutrophils | 1 | 2024 | 3771 | 0.090 |
Why?
|
Cost-Benefit Analysis | 3 | 2013 | 5531 | 0.090 |
Why?
|
Middle East | 1 | 2012 | 237 | 0.090 |
Why?
|
International Cooperation | 1 | 2018 | 1433 | 0.090 |
Why?
|
Diuretics | 1 | 2014 | 611 | 0.090 |
Why?
|
Anorexia Nervosa | 1 | 2020 | 1328 | 0.090 |
Why?
|
Hemodynamics | 2 | 2018 | 4188 | 0.090 |
Why?
|
Thoracoscopy | 1 | 2011 | 186 | 0.090 |
Why?
|
Immobilization | 1 | 2011 | 226 | 0.090 |
Why?
|
France | 1 | 2012 | 495 | 0.090 |
Why?
|
Surgery Department, Hospital | 1 | 2012 | 170 | 0.090 |
Why?
|
Lung | 4 | 2022 | 10063 | 0.090 |
Why?
|
Transplants | 1 | 2012 | 208 | 0.090 |
Why?
|
Myocardial Ischemia | 1 | 2021 | 2132 | 0.090 |
Why?
|
Leg | 2 | 2015 | 1088 | 0.090 |
Why?
|
Orthopedic Procedures | 1 | 2020 | 1279 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2662 | 0.080 |
Why?
|
Cross-Sectional Studies | 5 | 2020 | 26290 | 0.080 |
Why?
|
Coronary Disease | 2 | 2018 | 5919 | 0.080 |
Why?
|
Intubation, Intratracheal | 2 | 2015 | 1359 | 0.080 |
Why?
|
Medication Systems, Hospital | 1 | 2010 | 154 | 0.080 |
Why?
|
Quality of Health Care | 3 | 2015 | 4306 | 0.080 |
Why?
|
Africa | 1 | 2012 | 726 | 0.080 |
Why?
|
Germany | 1 | 2012 | 882 | 0.080 |
Why?
|
Mexico | 1 | 2012 | 772 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1943 | 0.080 |
Why?
|
Positive-Pressure Respiration | 1 | 2014 | 712 | 0.080 |
Why?
|
Forecasting | 1 | 2018 | 2936 | 0.080 |
Why?
|
Obesity, Morbid | 1 | 2020 | 1293 | 0.080 |
Why?
|
Mass Screening | 1 | 2024 | 5450 | 0.080 |
Why?
|
Critical Care | 1 | 2021 | 2714 | 0.080 |
Why?
|
Linear Models | 1 | 2018 | 5873 | 0.080 |
Why?
|
Hypolipidemic Agents | 1 | 2012 | 609 | 0.070 |
Why?
|
Brazil | 1 | 2012 | 1248 | 0.070 |
Why?
|
Critical Illness | 1 | 2020 | 2749 | 0.070 |
Why?
|
Heart | 1 | 2020 | 4419 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2018 | 6840 | 0.070 |
Why?
|
Adolescent | 6 | 2023 | 88819 | 0.070 |
Why?
|
Reminder Systems | 1 | 2010 | 388 | 0.070 |
Why?
|
Sarcoma, Kaposi | 1 | 2009 | 376 | 0.070 |
Why?
|
Cytological Techniques | 1 | 2008 | 217 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9237 | 0.070 |
Why?
|
Surgical Wound Infection | 1 | 2015 | 1544 | 0.060 |
Why?
|
Program Development | 1 | 2012 | 1297 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3530 | 0.060 |
Why?
|
Aspirin | 2 | 2020 | 3135 | 0.060 |
Why?
|
Cardiovascular Agents | 1 | 2012 | 848 | 0.060 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 1121 | 0.060 |
Why?
|
Health Resources | 1 | 2012 | 951 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2023 | 4863 | 0.060 |
Why?
|
Physicians | 1 | 2023 | 4591 | 0.060 |
Why?
|
Gastric Mucosa | 1 | 2008 | 602 | 0.060 |
Why?
|
Minority Groups | 1 | 2012 | 1208 | 0.060 |
Why?
|
Medical Records | 1 | 2010 | 1408 | 0.060 |
Why?
|
Models, Statistical | 1 | 2019 | 5089 | 0.060 |
Why?
|
Mortality | 3 | 2023 | 2911 | 0.060 |
Why?
|
Drug Costs | 1 | 2012 | 1195 | 0.060 |
Why?
|
Staining and Labeling | 1 | 2008 | 1072 | 0.060 |
Why?
|
Logistic Models | 4 | 2024 | 13273 | 0.060 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 3238 | 0.060 |
Why?
|
Equipment Safety | 1 | 2024 | 250 | 0.050 |
Why?
|
Biomedical Research | 2 | 2024 | 3458 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14747 | 0.050 |
Why?
|
Stents | 1 | 2015 | 3191 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9378 | 0.050 |
Why?
|
Quality Improvement | 2 | 2018 | 3849 | 0.050 |
Why?
|
Quality Indicators, Health Care | 1 | 2013 | 1804 | 0.050 |
Why?
|
Device Approval | 1 | 2024 | 164 | 0.050 |
Why?
|
Propensity Score | 2 | 2021 | 1973 | 0.050 |
Why?
|
Glioblastoma | 1 | 2017 | 3458 | 0.050 |
Why?
|
Phenotype | 1 | 2020 | 16716 | 0.050 |
Why?
|
Reoperation | 1 | 2012 | 4309 | 0.050 |
Why?
|
Lymphocyte Count | 1 | 2024 | 791 | 0.050 |
Why?
|
Cytokines | 1 | 2017 | 7426 | 0.050 |
Why?
|
Ventilation-Perfusion Ratio | 1 | 2021 | 115 | 0.050 |
Why?
|
Animals | 4 | 2020 | 168800 | 0.050 |
Why?
|
Platelet Count | 1 | 2024 | 784 | 0.050 |
Why?
|
Oxygen | 2 | 2023 | 4247 | 0.050 |
Why?
|
Hypertension, Pulmonary | 1 | 2012 | 1604 | 0.050 |
Why?
|
Hospitals | 1 | 2014 | 3887 | 0.040 |
Why?
|
Weight Loss | 1 | 2012 | 2711 | 0.040 |
Why?
|
Reference Values | 1 | 2008 | 4909 | 0.040 |
Why?
|
Lipids | 1 | 2011 | 3316 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2012 | 1878 | 0.040 |
Why?
|
Smoking Cessation | 1 | 2012 | 2084 | 0.040 |
Why?
|
Fibrinolysis | 1 | 2021 | 331 | 0.040 |
Why?
|
Prevalence | 3 | 2024 | 15827 | 0.040 |
Why?
|
Survival Analysis | 1 | 2013 | 10087 | 0.040 |
Why?
|
Patient Selection | 1 | 2012 | 4249 | 0.040 |
Why?
|
Mental Disorders | 1 | 2020 | 6871 | 0.040 |
Why?
|
Health Policy | 1 | 2012 | 2700 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2020 | 22228 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2021 | 427 | 0.040 |
Why?
|
Syncope | 1 | 2022 | 431 | 0.040 |
Why?
|
Phlebography | 1 | 2020 | 326 | 0.040 |
Why?
|
Disclosure | 1 | 2024 | 756 | 0.040 |
Why?
|
Thrombectomy | 1 | 2023 | 676 | 0.040 |
Why?
|
Data Collection | 2 | 2024 | 3318 | 0.040 |
Why?
|
Respiratory Care Units | 1 | 2018 | 10 | 0.040 |
Why?
|
Perfusion Imaging | 1 | 2020 | 193 | 0.040 |
Why?
|
Patient Advocacy | 1 | 2021 | 361 | 0.040 |
Why?
|
Smoking | 1 | 2015 | 9082 | 0.040 |
Why?
|
New York City | 1 | 2021 | 736 | 0.040 |
Why?
|
Republic of Korea | 1 | 2020 | 591 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 4 | 2023 | 20700 | 0.040 |
Why?
|
Systole | 1 | 2019 | 935 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2021 | 1985 | 0.040 |
Why?
|
Nutrition Surveys | 1 | 2024 | 1735 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 795 | 0.030 |
Why?
|
Young Adult | 4 | 2020 | 59868 | 0.030 |
Why?
|
Medication Errors | 1 | 2023 | 784 | 0.030 |
Why?
|
Tuberculosis | 1 | 2010 | 2010 | 0.030 |
Why?
|
Japan | 1 | 2021 | 1414 | 0.030 |
Why?
|
Cardiac Surgical Procedures | 1 | 2012 | 3682 | 0.030 |
Why?
|
Perfusion | 1 | 2021 | 1408 | 0.030 |
Why?
|
Patients | 1 | 2023 | 908 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 503 | 0.030 |
Why?
|
Drug Utilization | 2 | 2014 | 1187 | 0.030 |
Why?
|
Lymphocytes | 1 | 2024 | 2602 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2021 | 2915 | 0.030 |
Why?
|
Heart Transplantation | 1 | 2009 | 3307 | 0.030 |
Why?
|
Pain | 1 | 2011 | 5090 | 0.030 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.030 |
Why?
|
Renin-Angiotensin System | 1 | 2020 | 736 | 0.030 |
Why?
|
Vascular Surgical Procedures | 1 | 2024 | 1506 | 0.030 |
Why?
|
Coronary Angiography | 2 | 2021 | 4498 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2020 | 733 | 0.030 |
Why?
|
Polysomnography | 1 | 2022 | 1868 | 0.030 |
Why?
|
Health Services Research | 2 | 2013 | 1811 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2012 | 5510 | 0.030 |
Why?
|
Sternum | 1 | 2015 | 177 | 0.030 |
Why?
|
Obesity | 1 | 2017 | 13085 | 0.030 |
Why?
|
RNA, Viral | 1 | 2022 | 2868 | 0.030 |
Why?
|
Patient-Centered Care | 1 | 2024 | 1447 | 0.030 |
Why?
|
Catheter Ablation | 1 | 2007 | 2787 | 0.030 |
Why?
|
Blood Platelets | 1 | 2024 | 2464 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2844 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2020 | 1429 | 0.030 |
Why?
|
Respiration, Artificial | 1 | 2024 | 2727 | 0.030 |
Why?
|
Hospital Bed Capacity | 1 | 2014 | 200 | 0.030 |
Why?
|
Hypertension | 1 | 2013 | 8616 | 0.030 |
Why?
|
Dyspnea | 1 | 2020 | 1351 | 0.030 |
Why?
|
Rural Population | 1 | 2023 | 2318 | 0.020 |
Why?
|
Observer Variation | 1 | 2018 | 2611 | 0.020 |
Why?
|
Myocarditis | 1 | 2020 | 803 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2023 | 2778 | 0.020 |
Why?
|
Societies, Medical | 1 | 2024 | 3955 | 0.020 |
Why?
|
Access to Information | 1 | 2015 | 317 | 0.020 |
Why?
|
Peer Review, Research | 1 | 2015 | 342 | 0.020 |
Why?
|
Aftercare | 1 | 2017 | 915 | 0.020 |
Why?
|
Rural Health Services | 1 | 2014 | 393 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2009 | 5836 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2020 | 2255 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2020 | 4423 | 0.020 |
Why?
|
Herpesvirus 8, Human | 1 | 2009 | 254 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2008 | 570 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4086 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2017 | 2078 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2021 | 12775 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3387 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2008 | 956 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2009 | 13483 | 0.020 |
Why?
|
Wound Healing | 1 | 2015 | 2795 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3230 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3432 | 0.010 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2008 | 889 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2007 | 1394 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7871 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14645 | 0.010 |
Why?
|
Child | 1 | 2019 | 80573 | 0.010 |
Why?
|